Latest Insider Transactions at Dyne Therapeutics, Inc. (DYN)
This section provides a real-time view of insider transactions for Dyne Therapeutics, Inc. (DYN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dyne Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dyne Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,426
-5.91%
|
$1,004,058
$33.36 P/Share
|
|
May 20
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,426
+14.45%
|
$30,426
$1.03 P/Share
|
|
May 16
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,588
-1.09%
|
$72,464
$28.4 P/Share
|
|
May 16
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,738
-0.88%
|
$76,664
$28.4 P/Share
|
|
May 16
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,381
-0.79%
|
$66,668
$28.4 P/Share
|
|
May 16
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,705
-0.89%
|
$75,740
$28.4 P/Share
|
|
May 16
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,774
-1.0%
|
$77,672
$28.4 P/Share
|
|
Mar 12
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,030
-0.68%
|
$25,750
$25.58 P/Share
|
|
Mar 11
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,292
-1.44%
|
$57,300
$25.7 P/Share
|
|
Mar 11
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
19,601
-6.23%
|
$490,025
$25.59 P/Share
|
|
Mar 11
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,825
+10.08%
|
$89,125
$5.54 P/Share
|
|
Mar 11
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
66,387
-2.84%
|
$1,659,675
$25.89 P/Share
|
|
Mar 11
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.64%
|
$250,000
$5.54 P/Share
|
|
Mar 11
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,672
-1.1%
|
$66,800
$25.35 P/Share
|
|
Mar 11
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,585
-1.03%
|
$39,625
$25.7 P/Share
|
|
Mar 11
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,081
-1.35%
|
$52,025
$25.7 P/Share
|
|
Mar 08
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,199
-7.31%
|
$734,373
$27.04 P/Share
|
|
Mar 08
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
90,000
-14.43%
|
$2,340,000
$26.5 P/Share
|
|
Mar 08
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+14.56%
|
$450,000
$5.54 P/Share
|
|
Mar 08
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
363,343
-14.86%
|
$9,446,918
$26.47 P/Share
|
|
Mar 08
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
363,343
+18.22%
|
$1,816,715
$5.54 P/Share
|
|
Mar 08
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
86,252
-15.37%
|
$2,242,552
$26.45 P/Share
|
|
Mar 08
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
86,252
+17.11%
|
$431,260
$5.54 P/Share
|
|
Mar 07
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,591
-0.85%
|
$39,775
$25.85 P/Share
|
|
Mar 07
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,373
-1.51%
|
$59,325
$25.85 P/Share
|
|
Mar 07
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
9,086
-1.61%
|
$227,150
$25.85 P/Share
|
|
Mar 07
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,434
-1.69%
|
$60,850
$25.85 P/Share
|
|
Mar 07
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,921
-3.07%
|
$257,946
$26.0 P/Share
|
|
Mar 07
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,273
-1.83%
|
$56,825
$25.85 P/Share
|
|
Mar 01
2024
|
Atlas Venture Opportunity Fund I, L.P. |
SELL
Open market or private sale
|
Indirect |
17,099
-1.98%
|
$512,970
$30.05 P/Share
|
|
Mar 01
2024
|
Atlas Venture Opportunity Fund I, L.P. |
SELL
Open market or private sale
|
Direct |
29,435
-1.98%
|
$883,050
$30.05 P/Share
|
|
Mar 01
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
46,534
-1.98%
|
$1,396,020
$30.05 P/Share
|
|
Mar 01
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
9,311
-3.5%
|
$260,708
$28.43 P/Share
|
|
Mar 01
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
9,311
+6.52%
|
$9,311
$1.03 P/Share
|
|
Mar 01
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
24,260
-5.02%
|
$703,540
$29.0 P/Share
|
|
Mar 01
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,260
+12.63%
|
$0
$0.73 P/Share
|
|
Mar 01
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
94,480
-4.91%
|
$2,739,920
$29.06 P/Share
|
|
Mar 01
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
94,480
+12.56%
|
$472,400
$5.54 P/Share
|
|
Feb 29
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
3,429
-2.69%
|
$92,583
$27.5 P/Share
|
|
Feb 29
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,429
+2.62%
|
$3,429
$1.03 P/Share
|
|
Feb 29
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,268
-2.89%
|
$115,236
$27.5 P/Share
|
|
Feb 29
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,268
+2.81%
|
$0
$0.73 P/Share
|
|
Feb 29
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
5,520
-0.97%
|
$149,040
$27.5 P/Share
|
|
Feb 29
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
5,520
+0.96%
|
$27,600
$5.54 P/Share
|
|
Feb 28
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
190,920
-0.95%
|
$4,773,000
$25.04 P/Share
|
|
Feb 28
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
36,246
-0.76%
|
$906,150
$25.04 P/Share
|
|
Feb 28
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
154,674
-1.32%
|
$3,866,850
$25.04 P/Share
|
|
Feb 28
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
407
-0.25%
|
$10,175
$25.0 P/Share
|
|
Feb 27
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
368,699
-1.76%
|
$8,848,776
$24.53 P/Share
|
|
Feb 27
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
69,997
-1.43%
|
$1,679,928
$24.53 P/Share
|